ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Clinical Diabetes
Pyroptosis-Mediator Gasdermin D in Serum: A Potential Biomarker in Diabetic Kidney Disease
Provisionally accepted
- Hebei General Hospital, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To evaluate whether serum Gasdermin D (GSDMD) levels are associated with diabetic kidney disease (DKD) and renal function impairment, and to assess its potential diagnostic value. Methods: This cross-sectional observational study included 111 patients with DKD, 100 patients with non-diabetic kidney diseases, and 135 healthy controls. Serum GSDMD levels were measured using a chemiluminescence assay. Associations between GSDMD and clinical parameters were analyzed using Spearman correlation and binary logistic regression. Receiver operating characteristic (ROC) curves were constructed to evaluate diagnostic performance. Results: Serum GSDMD levels were significantly higher in patients with DKD than in healthy controls (p < 0.05). GSDMD levels were positively correlated with glucose (GLU), creatinine (CREA), blood urea nitrogen (BUN), and urinary albumin-to-creatinine ratio (UACR), and negatively correlated with estimated glomerular filtration rate (eGFR) (all p < 0.01). Multivariate logistic regression identified GSDMD as an independent factor associated with DKD. The area under the ROC curve (AUC) for GSDMD in identifying DKD was 0.847 (95% CI: 0.808–0.886), which increased to 0.933 (95% CI: 0.904–0.962) when combined with conventional indicators. Conclusion: Serum GSDMD levels are significantly associated with diabetic kidney disease and renal dysfunction. These findings suggest that GSDMD may serve as a complementary biomarker for DKD assessment; however, longitudinal and multicenter studies are required to confirm its prognostic value and clinical applicability.
Keywords: biomarker, Diabetic kidney disease, Gasdermin D, Inflammation, pyroptosis
Received: 28 Oct 2025; Accepted: 04 Feb 2026.
Copyright: © 2026 Ding, Wei, Liu, Liu, Huo, Yu and YANG. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lijing Huo
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.